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Background: There are evidence-based, guideline-directed medical therapies for HF with reduced ejection fraction (HFrEF), but their incremental 
cost-effectiveness has not been well studied using contemporary data.
specific aims: Our objective was to quantify the incremental cost-effectiveness ratio (ICER) of angiotensin converting enzyme inhibitor (ACEI), 
beta-blocker (BB), and aldosterone antagonist (AldA) therapy for patients with HFrEF.
methods: A Markov model with lifetime horizon and two states: dead or alive was created. We compared HFrEF patients treated with diuretics 
alone to three treatment arms: 1) ACEI 2) ACEI+BB 3) ACEI+BB+AldA. Sequential therapy was also analyzed. HF hospitalizations and mortality rates 
were based on representative studies. Costs of medications and inpatient and outpatient care were accounted for.
results: Treatment with ACEI and ACEI+BB strictly dominated (cost-saving) treatment with diuretic only. The greatest gains in quality-adjusted life-
years occurred when all 3 guideline-directed medications were provided. The incremental cost-effectiveness ratio (ICER) of ACEI+BB+AldA vs. ACEI+BB 
and ACEI+BB vs. ACEI was <$1500 per quality-adjusted life-year. The cost savings in the ACEI and ACEI+BB cohort compared to diuretics alone were 
$444 and $33 respectively. Assuming lower treatment costs and lower hospitalization rates in the ACEI+BB+AldA arm resulted in greater cost savings. 
Even in the most unfavorable situations, the ICER was <$10,000 per life-year gained.
conclusions: Our analysis demonstrates that medical treatment of HFrEF is highly cost-effective and may even result in cost-savings. Greater 
efforts to ensure optimal adherence to medical therapy for HFeEF are warranted.
